Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

Completed · Phase 2

Conditions studied: Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies

In brief

RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.

Key facts

Study ID

NCT00301873

Run by

Duke University

People needed

60

Starts

2006-05-01

Expected to finish

2012-09-01

Last updated by the study team

2013-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically confirmed diagnosis of a primary brain tumor.
• Patients must be on Depakote ( Valproic Acid) or one of the following enzyme inducing anticonvulsants (EIAC) therapies. Phenobarbital, Dilantin, Trileptal, Tegretol and/or on more than physiologic replacement steroid therapy (Dexamethasone >0.75 mg/d, prednisone >5 mg/d or hydrocortisone >20 mg/d).
• Age > 18 years.
• Karnofsky performance score > 60%
• Adequate renal and liver function as demonstrated by laboratory values performed within 14 days, inclusive, prior to the administration of Zometa, except for the creatinine, which will be within 72 hs of Zometa administration:
• Serum creatinine < 2.0 mg/dl and calculated creatinine clearance of >60 mL/min
• Total serum bilirubin < 1.5 times upper limit of laboratory normal
• Serum glutamoc-oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) < 2.5 times upper limit of laboratory normal
• Alkaline phosphatase of <2 times upper limit of laboratory normal
• Patients must have recovered from any effects of major surgery.
• Patients must have a life expectancy of greater than 12 weeks.
• Patients or legal guardian must give written, informed consent.

You may not qualify if…

• Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics.
• Previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.
• Known HIV positivity or AIDS-related illness.
• Pregnant or nursing women.
• Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 72hours prior to administration of study and be practicing medically approved contraceptive precautions.
• Men who are not advised to use and effective method of contraception.
• Patients previously diagnosed with osteoporosis requiring oral bisphosphonates.
• Known hypersensitivity to Zometa® (zoledronic acid) or other bisphosphonates
• Current active dental problems including infection of the teeth or jawbone osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
• Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).

Where it is running

• Duke Comprehensive Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.